AIM ImmunoTech Inc

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

AIM ImmunoTech reports promising clinical progress and financial stability

AIM ImmunoTech demonstrated strong clinical progress and financial stability, positioning the company well for future growth and potential partnerships.
While facing regulatory and operational challenges, the company's focus on expanding Ampligen's therapeutic applications and medical expertise presents significant opportunities for advancement.
Investors should monitor AIM ImmunoTech's continued progress in clinical trials and regulatory interactions, as positive outcomes could drive value creation and market expansion.

AIM ImmunoTech reports positive clinical progress and solid financial standing

AIM ImmunoTech's Q2 2024 Earnings Call highlighted significant progress in clinical trials for Ampligen, particularly in oncology indications.
Financially, the company maintains a solid cash position and continues to manage expenses to support ongoing operations and future milestones.
While facing challenges in trial design and cost management, AIM ImmunoTech remains well-positioned to capitalize on opportunities for growth and partnership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OCALA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones. Investors and other interested parties are invited to submit questions to management prior to the call's start via email to aim@crescendo-ir.com.

AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) has announced that all subjects have completed treatment in the Phase 1 clinical study to assess the safety, tolerability, and biological activity of its flagship drug Ampligen as a potential intranasal therapy. The Ocala, Florida-based immuno-pharma company said a final study report is expected in the third quarter of 2021.

AIM ImmunoTech completes Phase 1 clinical study of its flagship drug Ampligen

AIM ImmunoTech completes Phase 1 clinical study of its flagship Ampligen drug

Company is Planning a Phase 2 Study of its Drug as a Broad-Spectrum Respiratory Virus Prophylaxis Company is Planning a Phase 2 Study of its Drug as a Broad-Spectrum Respiratory Virus Prophylaxis

AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) reports that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential treatment option for cancer patients infected with SARS-CoV-2.  In a statement, the company said the study's authors stated that Ampligen has the potential to reduce the severity of the deadly respiratory disease COVID-19, which has so far caused more than 3.7 million deaths globally.

AIM ImmunoTech says Ampligen featured in medical journal as potential treatment for cancer patients infected with SARS-CoV-2

The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade Inhibitors The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade Inhibitors

AIM ImmunoTech's Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has entered into a two-year agreement extension with Shenzhen Smoore Technology Limited (Smoore) with the goal of developing Ampligen as a potential inhalation therapy for coronavirus (COVID-19) and other respiratory viral diseases.  In April 2020, AIM entered into the material transfer and research agreement to study the utilization of an innovative Smoore inhalation delivery device and Ampligen as a potential treatment approach for the SARS-CoV-2 pandemic.

AIM ImmunoTech extends pact with Shenzhen Smoore Technology to develop Ampligen as inhalation therapy for coronavirus, other respiratory diseases

Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive

AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen

OCALA, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events.

AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Thomas Equels told investors that the immuno-pharma company rounded out the first quarter by increasing its cash reserves to “aggressively move forward” with its clinical programs.       As of March 31, 2021, the Ocala, Florida-based company had cash, cash equivalents, and marketable securities of $63.6 million, compared to $54.4 million as of December 31, 2020.

AIM ImmunoTech CEO says the firm in ‘solid financial standing' to move forward rapidly with clinical programs

OCALA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021.

AIM ImmunoTech Provides First Quarter 2021 Business Update

OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat' video interview with Ed Woo, Director of Research & Senior Analyst at Ascendiant Capital Markets.

AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) said it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability, and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events (SAE).  The company, which also reported no SAEs in Cohort 1, said the study will proceed with enrollment into Cohort 3.

AIM ImmunoTech reports positive safety data in Cohort 2 of Phase 1 clinical study of Ampligen as an intranasal therapy

OCALA, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events (SAE). AIM also reported no SAEs in Cohort 1. The study will proceed with enrollment into Cohort 3.

AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases

AIM ImmunoTech Inc (NYSE: AIM) has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases. The company reported no serious adverse events, thus paving the way for dose escalation in Cohort 2.

AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of its Ampligen drug as an intranasal therapy and reported no serious adverse events.   The company said the positive safety data paves the way for an escalation of the dose in Cohort 2 and is a critical step in its ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for coronavirus (COVID-19) and other respiratory viral diseases.

AIM ImmunoTech reports no serious adverse events in dosing of Cohort 1 in Phase 1 study of Ampligen drug's safety as an intranasal therapy

OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM's drug Ampligen as an intranasal therapy, reporting no serious adverse events, and paving the way for escalation of the dose in Cohort 2. The trial is a critical step in the company's ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.

AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that it ended 2020 with cash, cash equivalents, and marketable securities of $54.4 million.  That's a sizable increase compared to the $8.8 million in cash it recorded as of December 31, 2019, according to a statement.

AIM ImmunoTech headed in 2021 with $54.4M in capital as it advances Ampligen to treat COVID-19 and cancer

OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update.

AIM ImmunoTech Reports 2020 Year-End Financial Results

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) has announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center has approved a protocol amendment to Roswell Park's ongoing Phase 1/2a study evaluating the two-drug combination of AIM's Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate coronavirus (COVID-19). AIM ImmunoTech said the IRB-approved amendment calls for randomization of an additional 20 patients.

AIM ImmunoTech announces addition of single-agent Ampligen arm to ongoing study of cancer patients with coronavirus

OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a protocol amendment to Roswell Park's ongoing Phase 1/2a study evaluating the two-drug combination of AIM's Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate COVID-19.

AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center's Ongoing Study in Cancer Patients with COVID-19

Asensus Surgical

Celsion

iBio

Jaguar Health

Ovid Therapeutics

Rigel Pharmaceuticals

VBI Vaccines

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

8 Biotech Penny Stocks for Investors to Watch

OCALA, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM's Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC.

AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Monday that it has dosed the first healthy subjects in its Phase 1 clinical study of Ampligen as a potential intranasal therapy for the coronavirus (CVOID-19) and other respiratory viral diseases. The current study plans call for the enrollment of eight healthy subjects in each of four Ampligen treatment groups and eight placebo subjects, for a total of 40 healthy subjects, the company said.

AIM ImmunoTech doses first healthy subject in intranasal Ampligen coronavirus study

Marks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases Marks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases

News for AIM ImmunoTech Inc Stock (AIM)